Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 159,100 shares at $68.48 ($10.9M) on 2026-03-12, disclosed to the SEC on 2026-03-16.
Scheduled sale ($10.9M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $68.47 | 13,885 | $951K | 8.7% |
| 2 | $68.47 | 13,885 | $951K | 8.7% |
| 3 | $68.48 | 14,337 | $982K | 9.0% |
| 4 | $68.48 | 14,337 | $982K | 9.0% |
| 5 | $69.29 | 5,815 | $403K | 3.7% |
| 6 | $69.29 | 5,815 |
| $403K |
| 3.7% |
| 7 | $69.32 | 5,363 | $372K | 3.4% |
| 8 | $69.32 | 5,363 | $372K | 3.4% |
| 9 | $70.15 | 300 | $21K | 0.2% |
| 10 | $68.36 | 9,690 | $662K | 6.1% |
| 11 | $68.36 | 9,690 | $662K | 6.1% |
| 12 | $68.39 | 10,241 | $700K | 6.4% |
| 13 | $68.39 | 10,241 | $700K | 6.4% |
| 14 | $69.20 | 10,310 | $713K | 6.5% |
| 15 | $69.20 | 10,310 | $713K | 6.5% |
| 16 | $69.23 | 9,759 | $676K | 6.2% |
| 17 | $69.23 | 9,759 | $676K | 6.2% |
| Total | $68.76 avg | 159,100 | $10.9M | 100% |
| Filing → |
| BBIO | SELL | 2026-06-08 | $4.6M | — | Filing → |
| BBIO | SELL | 2026-05-26 | $1.8M | — | Filing → |
| BBIO | SELL | 2026-05-11 | $5.3M | — | Filing → |